# BATCH2-REMAINING-BLOCKERS-1 — Remaining Batch 2 Blocker Resolution and Gated Activation

**Work ID:** `BATCH2-REMAINING-BLOCKERS-1_remaining_batch2_blocker_resolution_and_gated_activation`  
**Date:** 2026-06-07  
**SOP:** AUTOMATION_BUS_SOP_v1.3.1

---

## Executive verdict

**READY_FOR_HUMAN_STOP_GATE.** All **11** remaining inactive Batch 2 packages received final blocker adjudication. **Zero packages** proposed for activation. **No runtime code changes.** **No clinical wording or threshold changes.** Formal blockers recorded in `batch2_remaining_blockers_execution_register_v1.yaml`. Consolidated platform capability blocker: **CF-CONTEXT-MOD-3** (androgen + FT3 low illness context). eGFR deferred to **BATCH2-EGFR-AUTHORITY-1**.

---

## Artefacts inspected

| Artefact | Status |
|----------|--------|
| `batch2_remainder_resolution_register_v1.yaml` | Read — investigation baseline |
| `batch2_thyroid_gate_execution_register_v1.yaml` | Read — 3 thyroid activated; FT3 low deferred |
| `batch2_runtime_activation_execution_register_v1.yaml` | Read |
| `batch2_final_promotion_decision_register_v1.yaml` | Read |
| `batch2_androgen_panel_medical_review_v1.yaml` | Read |
| `batch2_androgen_context_modifier_binding_v1.yaml` | Read |
| `medical_frame_identity_index_v1.yaml` | Read — not modified |
| `context_modifier_catalogue_draft_v1.yaml` | Read — `runtime_consumed: false`; all modifiers `runtime_active: false` |
| `thyroid_blood_marker_interpretation_clinical_signoff.md` | Read |
| All 11 in-scope package directories | Inspected (manifest/signal_library read-only) |
| `backend/core/analytics/signal_evaluator.py` | Read — mandatory_pre_emission_gates present; no context modifier path |

---

## 11-package decision table

| package_id | current_state | known_blocker | can_be_safely_gated_now | requires_runtime_code_change | requires_medical_research | requires_architecture_decision | recommended_action |
|------------|---------------|---------------|:-----------------------:|:----------------------------:|:-------------------------:|:------------------------------:|--------------------|
| pkg_kb47_free_t3_low_low_t3_syndrome | gov-promoted, inactive | TSH+FT4+illness/medication context | No | Yes (Layer B context) | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_dhea_high_androgen_excess_context | never promoted | clinical sign-off + context | No | Yes | Yes | No | KEEP_BLOCKED_MEDICAL_SIGNOFF_REQUIRED |
| pkg_kb47_dhea_low_adrenal_androgen_reduction | never promoted | sex/age/SHBG/medication context | No | Yes | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_fai_high_biochemical_hyperandrogenism | never promoted | SHBG/sex context | No | Yes | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_fai_low_reduced_free_androgen_availability | never promoted | SHBG/sex context | No | Yes | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_free_testosterone_high_androgen_excess_context | never promoted | clinical sign-off + context | No | Yes | Yes | No | KEEP_BLOCKED_MEDICAL_SIGNOFF_REQUIRED |
| pkg_kb47_free_testosterone_low_androgen_deficiency_context | never promoted | sex/age/medication context | No | Yes | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_free_testosterone_pct_high_elevated_free_androgen_fraction | never promoted | SHBG fraction context | No | Yes | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_free_testosterone_pct_low_reduced_free_androgen_fraction | never promoted | SHBG fraction context | No | Yes | No | No | KEEP_BLOCKED_RUNTIME_CAPABILITY_MISSING |
| pkg_kb47_egfr_low_chronic_kidney_function_reduction | never promoted | renal authority / collision | No | Yes | No | Yes | KEEP_BLOCKED_AUTHORITY_DECISION_REQUIRED |
| pkg_kb47_egfr_low_hemodynamic_filtration_drop | never promoted | anti-double-counting | No | Yes | No | Yes | KEEP_BLOCKED_AUTHORITY_DECISION_REQUIRED |

---

## Phase 2 — eGFR renal authority decision

| Question | Answer |
|----------|--------|
| 1. Is eGFR-low allowed to become an independent runtime signal? | **Not safely today** — no authority adjudication completed |
| 2. Does eGFR-low duplicate creatinine-high / eGFR escalation? | **Yes, risk confirmed** — same `signal_egfr_low` family; creatinine canonical + legacy eGFR override active |
| 3. Are anti-double-counting rules already present? | **No** — SignalEvaluator has no renal collision suppression |
| 4. Can both coexist safely with metadata alone? | **No** — would require architecture authority model |
| 5. Should eGFR remain inactive? | **Yes** — both packages remain inactive |

**Formal blocker:** `renal_authority_and_anti_double_counting_required`  
**Required next action:** BATCH2-EGFR-AUTHORITY-1

---

## Phase 3 — androgen context-gated decision

| Check | Result |
|-------|--------|
| 1. Sex and age available at runtime to SignalEvaluator? | Demographics exist in questionnaire SSOT but **not consumed** by evaluator |
| 2. SHBG available as biomarker input to gate? | Biomarker may be present in panel but **no context gate path** in evaluator |
| 3. Medication/hormone/steroid/supplement context runtime-consumed? | **No** — catalogue `runtime_consumed: false` |
| 4. Context modifiers runtime-active? | **No** — all `runtime_active: false` |
| 5. Can signal be suppressed unless context exists? | **Not with current architecture** — no fail-closed context gate mechanism |
| 6. Would activation risk misleading interpretation? | **Yes** — all 8 packages remain blocked |

**Formal blocker:** `androgen_runtime_context_evaluation_required`  
**Required next action:** CF-CONTEXT-MOD-3 + CF-BATCH2-010 (clinical sign-off)

---

## Phase 4 — FT3 low decision

| Check | Result |
|-------|--------|
| 1. Can TSH presence be required? | Mechanism exists (`mandatory_pre_emission_gates`) but **insufficient alone** |
| 2. Can FT4 presence be required? | Same — biomarker_present gate possible but **insufficient alone** |
| 3. Can illness/medication context be required? | **No** — not runtime-consumed |
| 4. Is illness/medication context runtime-consumed? | **No** — CF-CONTEXT-MOD-3 open |
| 5. Safe context-missing emission state? | **Rejected** — sign-off prohibits partial activation |

**Formal blocker:** `ft3_low_requires_layer_b_context`  
**Required next action:** CF-CONTEXT-MOD-3

Partial TSH+FT4 biomarker gates **not implemented** — would not satisfy clinical sign-off (STOP condition 5).

---

## Gates implemented

**None.** No package met the bar for safe fail-closed gating without Layer B context or renal authority architecture.

---

## Packages proposed for activation

**None.**

---

## Packages remaining blocked (11)

| Group | Count | Blocker |
|-------|------:|---------|
| FT3 low | 1 | `ft3_low_requires_layer_b_context` |
| Androgen | 8 | `androgen_runtime_context_evaluation_required` |
| eGFR | 2 | `renal_authority_and_anti_double_counting_required` |

---

## Tests added / updated

**None required** — no runtime or signal_library changes.

Existing thyroid gating regression (`test_batch2_thyroid_tsh_gating.py`) confirms activated thyroid packages and inactive FT3 low unchanged.

---

## Validation output

**Architecture gate:** PASS

```text
architecture_validation_gate: PASS
medical_frame_identity_index: PASS (errors: 0)
context_modifier_catalogue: PASS (errors: 0)
day_one_architecture_validation: PASS
medical_intelligence_architecture_validation: PASS
pytest_architecture_guardrails: PASS
pytest_governance_regression: PASS
```

**Frame index validator:** PASS (errors: 0)

**Context modifier catalogue validator:** PASS (errors: 0)

**Package validators (11 remaining):** all PASS — `validation_status: PASS`, `errors: 0`, `ready_for_implementation: True`

**Thyroid gating regression (sanity — activated packages unaffected):** 11/11 PASS

---

## STOP gate outcome

**Status:** `READY_FOR_HUMAN_STOP_GATE`

**Approval received:** No

**Required phrase:** `APPROVE BATCH2 REMAINING GATED ACTIVATION`

**Runtime activation performed:** No

**If approval received with zero qualifying packages:** Sprint closes with all 11 formally blocked — no metadata activation warranted.

---

## Rollback path

1. Revert `batch2_remaining_blockers_execution_register_v1.yaml`
2. Revert this audit report
3. Revert carry-forward register updates

No runtime code, package clinical content, frame index, or manifest activation metadata changed.

---

## Carry-forward updates

| ID | Action |
|----|--------|
| CF-BATCH2-007 | **Resolved** — eGFR formally blocked with final blocker `renal_authority_and_anti_double_counting_required`; next BATCH2-EGFR-AUTHORITY-1 |
| CF-BATCH2-010 | **Open** — androgen clinical sign-off still required; formal runtime blocker recorded |
| CF-CONTEXT-MOD-3 | **Open** — scope expanded to FT3 low illness/medication context + all 8 androgen packages |

---

## Confirmations

- No clinical wording changes
- No threshold or reference range changes
- No signal IDs or activation keys changed
- No frontend / SSOT / scoring / report compiler changes
- No unrelated runtime behaviour changes
- Already-active Batch 2 packages untouched

---

## Files changed

```text
knowledge_bus/governance/batch2_remaining_blockers_execution_register_v1.yaml (new)
docs/audit-papers/BATCH2-REMAINING-BLOCKERS-1_remaining_batch2_blocker_resolution_and_gated_activation.md (new)
docs/sprints/launch_core_carry_forward_register.md (updated)
```
